In a deal worth approximately $230 million, Roche has signed an agreement to acquire Anadys Pharmaceuticals according to a Roche press release issued Oct. 17, 2011. Citing aims to bolster future treatment options for hepatitis C, the merger will see Roche fully acquiring Anadys at a share price of $3.70 in an all-cash transaction
http://www.roche.com/media/media_releases/med-cor-2011-10-17.htm